

Jürgen Agnholt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8532581/publications.pdf>

Version: 2024-02-01

24
papers

570
citations

932766

10
h-index

752256

20
g-index

24
all docs

24
docs citations

24
times ranked

1243
citing authors

#	ARTICLE	IF	CITATIONS
1	Paediatric Crohn's Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. <i>GastroHep</i> , 2022, 2022, 1-11.	0.3	0
2	Effectiveness of infliximab treatment of complex idiopathic anal fistulas. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 391-396.	0.6	1
3	Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn's Disease during One-Year Follow-Up. <i>Nutrients</i> , 2021, 13, 1083.	1.7	12
4	Effectiveness of interdisciplinary combined dermatology-gastroenterology-rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial. <i>BMJ Open</i> , 2021, 11, e041871.	0.8	8
5	Reply. <i>Gastroenterology</i> , 2021, 161, 2068-2069.	0.6	0
6	Decrease in Mucosal IL17A, IFN γ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab. <i>Nutrients</i> , 2020, 12, 3699.	1.7	11
7	Letter: post-infective bile acid malabsorption and diarrhoea. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 110-111.	1.9	0
8	The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis. <i>BMC Gastroenterology</i> , 2019, 19, 83.	0.8	10
9	Efficacy of Injection of Freshly Collected Autologous Adipose Tissue Into Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 156, 2208-2216.e1.	0.6	72
10	Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 964-967.	0.8	3
11	Letter: long-term treatment of severe bile acid diarrhoea-obeticholic acid can normalise SeHCAT retention. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1034-1035.	1.9	0
12	Effects of Anti-TNF Treatment on Mucosal Expression of IL-17A, IL-21, and IL-22 and Cytokine-Producing T Cell Subsets in Crohn's Disease. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	1.4	2
13	Current, experimental, and future treatments in inflammatory bowel disease: a clinical review. <i>Immunopharmacology and Immunotoxicology</i> , 2018, 40, 446-460.	1.1	30
14	Immune responses and parasitological observations induced during probiotic treatment with medicinal <i>Trichuris suis ova</i> in a healthy volunteer. <i>Immunology Letters</i> , 2017, 188, 32-37.	1.1	22
15	Vitamin D increases programmed death receptor-1 expression in Crohn's disease. <i>Oncotarget</i> , 2017, 8, 24177-24186.	0.8	26
16	Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study. <i>European Journal of Clinical Investigation</i> , 2016, 46, 555-563.	1.7	25
17	Reduced numbers of mucosal DR ^{int} macrophages and increased numbers of CD103 ⁺ dendritic cells during anti-TNF- α treatment in patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 692-699.	0.6	25
18	Effects of Arabinoxylan and Resistant Starch on Intestinal Microbiota and Short-Chain Fatty Acids in Subjects with Metabolic Syndrome: A Randomised Crossover Study. <i>PLoS ONE</i> , 2016, 11, e0159223.	1.1	123

#	ARTICLE	IF	CITATIONS
19	Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	1.4	10
20	Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2014, 109, 1749-1756.	0.2	81
21	The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF- α therapy. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 521-528.	0.6	9
22	Increased production of granulocyte- α macrophage colony-stimulating factor in Crohn's disease - a possible target for infliximab treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 649-655.	0.8	39
23	The effect of etanercept and infliximab on the production of tumour necrosis factor α , interferon- γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures. <i>Cytokine</i> , 2003, 23, 76-85.	1.4	55
24	T-cell vaccination in Crohn's disease: principles and presentation of the first two cases. <i>Cytokines, Cellular & Molecular Therapy</i> , 2002, 7, 117-123.	0.3	6